Cholesterol Self-testing in Patients Post Acute Coronary Syndrome
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversity of Leipzig
About this trial
The pharmacological reduction of LDL-C lowers cardiovascular risk and is therefore a priority in cardiovascular secondary prevention. The achievement of LDL-C target levels in Germany, Europe, and worldwide is inadequate, despite a wide array of lipid-lowering medications. Only a small proportion of post-myocardial infarction patients reach their LDL-C target range within a year. There is a significant need for new strategies to improve LDL-C target achievement and thereby reduce the occurrence of secondary cardiovascular events.
The aim of the study is to establish a basis for improving prevention by achieving the target LDL level effectively and quickly in patients with high and very high cardiovascular risk profiles.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Age ≥ 18 years
Patients with acute coronary syndrome in the last 6 months and not having reached the LDL target value
Signed informed consent
Disqualifiers
Persons unable to understand the study
Persons unable or unwilling to perform self-measurements
Persons unable or unwilling to undergo additional cholesterol-lowering therapy to reach the LDL target
Pre-menopausal women without contraception
Trial design
Design model
Parallel
Treatments tested in this trial
Cholesterol self-measurement
Other interventionPatients will be trained to use a device to self-measurement of cholesterol-values monthly. After the measurement they will report their results to study team for ajusting the therapy.
Treatment groups
200 Participants
are divided into 2 treatment groupsGroup A: Standard of careNo intervention 0 interventions
Group B: Cholesterol self-measurementExperimental treatment 1 intervention
Trial outcomes
Primary outcomes
1
percentage value LDL-Cholesterol reduction in comparison to baseline
Compare the change in value of LDL-Cholesterol with additional monthly self measurement of parameters after 6 months versus baseline and the control group.
Time frame
6 monthsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov